Tafasitamab (MOR208) in relapsed or refractory follicular lymphoma: a promising frontier in targeted immunotherapy.
0/5 보강
APA
Ahmad M, Kalam H (2025). Tafasitamab (MOR208) in relapsed or refractory follicular lymphoma: a promising frontier in targeted immunotherapy.. Annals of medicine and surgery (2012), 87(12), 7866-7867. https://doi.org/10.1097/MS9.0000000000004016
MLA
Ahmad M, et al.. "Tafasitamab (MOR208) in relapsed or refractory follicular lymphoma: a promising frontier in targeted immunotherapy.." Annals of medicine and surgery (2012), vol. 87, no. 12, 2025, pp. 7866-7867.
PMID
41377405 ↗
같은 제1저자의 인용 많은 논문 (5)
- Letter to the Editor: Clinical Considerations in Interpreting a Multi-Target Blood Protein Test for Colorectal Cancer.
- Ubiquitination of Oncogenic Mutant p53 via Attenuation of Ribosome Biogenesis Machinery Effectively Inhibits Pancreatic Tumor Growth.
- LINAC stereotactic radiosurgery for vestibular schwannomas.
- Trends and Disparities in Mortality Due to Gastric Malignancies the United States: A Nationwide Analysis from 1999 to 2020.
- Mitochondrial ribosomal protein L3 (MRPL3): An early diagnostic biomarker and potential molecular target in pancreatic cancer.